1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Isracann Biosciences Inc.

Isracann Biosciences Inc.

ISCNF
Isracann Biosciences Inc.US flagOther OTC
0.00
USD
- -
- -
1,760.00Market Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
- -
- -
- -
- -
0.01
0.03
0.06
0.05
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.07
-0.03
-0.04
-0.04
-0.15
-0.09
-0.12
-0.33
-0.25
-0.26
-0.18
-0.03
-0.03
Free Cash Flow per Basic Share
-0.07
-0.03
-0.04
-0.04
-0.18
-0.03
-0.1
-0.39
-0.08
-0.12
-0.03
-0.01
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.09
-0.11
-0.15
-0.19
-0.26
-0.28
-0.04
0.09
-0.2
0.14
-0.07
-0.09
-0.09
Tangible Book Value per Share
0.19
0.13
0.1
0.06
0.12
0.06
0.01
0.6
0.4
0.06
0.03
-0.02
-0.02
Basic Weighted Avg Shares
2
2
2
2
4
6
6
23
38
93
138
148
150
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
-1,531.75
-232.98
-171.06
-535.45
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
-1
- -
-1
-7
-10
-24
-25
-5
-5
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
-1,531.75
-261.34
-207.76
-636.91
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
8
14
4
2
-1
-1
LT Debt
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
1
1
- -
14
15
27
4
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Feb'22
May'22
Aug'23
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
146
158
163
Market Capitalization
14
9
8

Working Capital

FRC

•

in mil. unless spec.
Feb'22
May'22
Aug'23
Total Current Assets
1
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1,693.93%
3,292.51%
-92.62%
Free Cash Flow
248.6%
307.4%
-58.65%
Net Income, GAAP
166.09%
224.35%
-81.34%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
-0.01
-0.01
- -
-0.18
2022
- -
-0.01
- -
- -
-0.03
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Ajay Singh Kaila
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
595 Burrard Street Vancouver BC Canada V7X 1L3
IPO Date
Dec 15, 2017
Website
isracann.com
Similar Companies
DURECT Corporation (DRRX)
Mithra Pharmaceuticals S.A. (MITRA.BR)
Zhengye Biotechnology Holding Limited (ZYBT)
Avivagen Inc. (VIVXF)
TerrAscend Corp. (TER.CN)
Columbia Care Inc. (CCHWF)
Business
Isracann Biosciences Inc. cultivates and distributes medical cannabis in Israel through its subsidiaries; develops cultivation facilities targeting domestic Israeli demand and exports to Germany and European markets; and commercializes natural health products including post-viral prophylaxis, urological treatments, anxiety aids, immune boosters, and sleep formulations with and without cannabinoids or psilocybin via its Praesidio Health Inc. subsidiary. The company operates primarily in the medical cannabis and natural health sectors, serving healthcare providers, patients, and international distributors from facilities in Israel's Sharon Plain and Nir Israel regions, including joint ventures for scalable farms expandable to over 160,000 square feet. Founded in 2010 and headquartered at 595 Burrard Street, Suite 1600, Vancouver, British Columbia, Canada, Isracann was formerly Atlas Blockchain Group Inc. prior to its name change in October 2019. In April 2022, Isracann completed the acquisition of Praesidio Health Inc., enhancing its natural health product pipeline and appointing specialized officers to advance clinical strategies; it entered joint venture agreements for near-term cannabis farm production in Israel's Sharon Plain, committing up to CAD$2.7 million for 50% economic interests pending regulatory approvals. The company's CSE listing (IPOT) was delisted in September 2024, with prior management changes in January 2024 including director and officer resignations.

Company News

APIChatGPT

  • newsfilecorp.com

    CSE Bulletin: Delist - Isracann Biosciences Inc. (IPOT)

  • seekingalpha.com

    Searching For Cannabis Catalysts (Podcast Transcript)

  • globenewswire.com

    Isracann Announces Launch of Early Warrant Exercise Incentive Program and Repricing